TERT and glioblastoma: The majority of glioblastoma cases (70–90%) exhibit mutations in the TERT promoter, specifically the C228T or C250T variants, which are located at positions −124 bp and −146 bp before the TERT translation start site (5p15.33).These mutations involve the conversion of cytosine to thymine at two specific positions: 1295228 C > T and 1295250 C > T, as documented by Arita et al. in 2016 [111].